Abstract
Background: This study examines national childhood HSV mortality data in Australia from 1999-2011. This information is important to better understand the disease burden of HSV in early life and to formulate public health interventions. Methods: Retrospective analysis of Australian Bureau of Statistics (ABS) national mortality data from 1999- 2011 in children aged <15 years who died with specific ICD-10 codes for HSV infection listed as an underlying or contributing cause. Results: Twenty nine HSV-associated deaths in children aged <15 years from 1999-2011 were identified (0.05 per 100,000 children; 95% CI 0.04-0.06), 16 in the first month of life (0.45 per 100,000 live births; 95% CI 0.23- 0.67). Among those, 20 were males and 9 were females (p=0.04). The majority of deaths (69%) occurred in infants aged <12 months and most in infants aged <1 month (55%). HSV-associated death in infants aged < 1 month of age accounted for 0.15% of all neonatal deaths for 1999-2011 in Australia. A downward trend in HSV-associated neonatal mortality was observed between 1999 and 2011 (p=0.52). During the study period, mortality from HSV infections in Australian children resulted in an estimated 2,275 age-adjusted years of potential life lost. Conclusions: This data confirms reported findings from active surveillance of a downward trend in mortality rate from HSV infection in infants aged < 1 month in Australia over this period. Ongoing surveillance is required to confirm this observation.
Keywords: Children, Herpes simplex virus (HSV), mortality, neonate.
Infectious Disorders - Drug Targets
Title:Mortality from Herpes Simplex Virus (HSV) Infection in Australian Children, 1999-2011 Using National Datasets
Volume: 14 Issue: 2
Author(s): Gulam Khandaker, Camille Raynes-Greenow, Hayley Smithers-Sheedy, Robert Booy, Robert Menzies and Cheryl Jones
Affiliation:
Keywords: Children, Herpes simplex virus (HSV), mortality, neonate.
Abstract: Background: This study examines national childhood HSV mortality data in Australia from 1999-2011. This information is important to better understand the disease burden of HSV in early life and to formulate public health interventions. Methods: Retrospective analysis of Australian Bureau of Statistics (ABS) national mortality data from 1999- 2011 in children aged <15 years who died with specific ICD-10 codes for HSV infection listed as an underlying or contributing cause. Results: Twenty nine HSV-associated deaths in children aged <15 years from 1999-2011 were identified (0.05 per 100,000 children; 95% CI 0.04-0.06), 16 in the first month of life (0.45 per 100,000 live births; 95% CI 0.23- 0.67). Among those, 20 were males and 9 were females (p=0.04). The majority of deaths (69%) occurred in infants aged <12 months and most in infants aged <1 month (55%). HSV-associated death in infants aged < 1 month of age accounted for 0.15% of all neonatal deaths for 1999-2011 in Australia. A downward trend in HSV-associated neonatal mortality was observed between 1999 and 2011 (p=0.52). During the study period, mortality from HSV infections in Australian children resulted in an estimated 2,275 age-adjusted years of potential life lost. Conclusions: This data confirms reported findings from active surveillance of a downward trend in mortality rate from HSV infection in infants aged < 1 month in Australia over this period. Ongoing surveillance is required to confirm this observation.
Export Options
About this article
Cite this article as:
Khandaker Gulam, Raynes-Greenow Camille, Smithers-Sheedy Hayley, Booy Robert, Menzies Robert and Jones Cheryl, Mortality from Herpes Simplex Virus (HSV) Infection in Australian Children, 1999-2011 Using National Datasets, Infectious Disorders - Drug Targets 2014; 14 (2) . https://dx.doi.org/10.2174/1871526514666140714084934
DOI https://dx.doi.org/10.2174/1871526514666140714084934 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Forkhead Transcription Factor FOXO3a Controls Microglial Inflammatory Activation and Eventual Apoptotic Injury through Caspase 3
Current Neurovascular Research Recent Advances in Marine Algal Anticoagulants
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Impact of Latent Viral Infections in Mechanically Ventilated Patients
Current Respiratory Medicine Reviews Antiidiotype-Derived Killer Peptides As New Potential Tools to Combat HIV-1 and AIDS-Related Opportunistic Pathogens
Anti-Infective Agents in Medicinal Chemistry Medicinal Plants with anti-Acanthamoeba Activity: A Systematic Review
Infectious Disorders - Drug Targets Evasion of Ribonuclease Inhibitor as a Determinant of Ribonuclease Cytotoxicity
Current Pharmaceutical Biotechnology Uracils as a Cellular Weapon Against Viruses and Mechanisms of Viral Escape
Current HIV Research Novel Nucleic Acid-Based Agents: siRNAs and miRNAs
Central Nervous System Agents in Medicinal Chemistry Research Progress of Glycyrrhizic Acid on Antiviral Activity
Mini-Reviews in Medicinal Chemistry Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Immune Checkpoint Inhibitors and Neurotoxicity
Current Neuropharmacology Dorsal Stream Dysfunction in Children. A Review and an Approach to Diagnosis and Management
Current Pediatric Reviews Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials SARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines?
Current Molecular Medicine Experimental and Clinical Application of Plasmid DNA in the Field of Central Nervous Diseases
Current Gene Therapy Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
Current Neuropharmacology Therapeutic Potential of Erythropoietin in Retinal and Optic Nerve Diseases
CNS & Neurological Disorders - Drug Targets Delivery of Anti-Viral Nucleoside Analogues to the Central Nervous System
Current Medicinal Chemistry - Anti-Infective Agents Catatonia, Malignant Catatonia, and Neuroleptic Malignant Syndrome
Current Psychiatry Reviews The CCL2/CCR2 Axis in the Pathogenesis of HIV-1 Infection: A New Cellular Target for Therapy?
Current Drug Targets